There is now overwhelming evidence that alterations in lipid metabolism underlie the pathogenesis of atherosclerotic cardiovascular disease (CVD). However, research in this area has primarily focused on abundant plasma lipids such as cholesterol, triglycerides, and oxidized phospholipids that are largely carried on circulating lipoproteins 1, 2 . Circulating levels of abundant lipids can provide valuable information for CVD risk stratification, yet the majority of CVD risk cannot be explained by traditional lipid risk factors 3 . Over the last decade there have been rapid advances in mass spectrometry-based methods to comprehensively annotate the entire "lipidome", which includes a large variety of lipid molecular species including non-lipoprotein associated lipids and less abundant signaling lipids that impact disease. This new field of "lipidomics" provides a powerful platform for identification of potential lipid biomarker signatures predicting disease risk, but also provides clues into novel lipid metabolic pathways that may be directly involved in the pathogenesis of disease. At an amazingly rapid pace ( Figure   1 ), lipidomic approaches have yielded valuable information linking specific lipid types with structural and signaling roles in the development of cancer 4 , obesity 5 , diabetes 6 , hypertension 7 , alzheimer's disease 8 , infectious diseases 9 , and CVD 10 . Undoubtedly, lipidomic approaches provide a powerful discovery platform that have promise to both identify new biomarkers of chronic disease, and provide clues into unrecognized lipid metabolic pathways with potential mechanistic links to disease pathogenesis and untapped therapeutic potential.
In this issue of Circulation, Stegemann and colleagues 11 apply a targeted lipidomic approach to population-based cohorts with documented CVD events. The purpose of this editorial is to summarize the results from this seminal study and discuss the implications of identifying a lipid signature that predicts CVD risk. To begin, it is important to discuss the broad field of lipidomics, and its rapid development over the last decade. While lipids are among the "lipidomics" provides a powerful platform for identification of potential lipid bio io oma ma ark rk ker er er ignatures predicting disease risk, but also provides clues into novel lipid metabolic pathways h hat at t m m ma ay ay b b be e e di d d re ect ct ctl ly ly involved in the pathogenesi i is s s of f disease. At an an n ama ma azi zi zing n ly rapid pace ( Figure   1 1) ), l l lip i idomic a app pp pro o oac ache he h s s s ha ha have ve ve y yie ie eld ld lded ed v va alua a abl l le in nf nfo o orm ma mat ti tion on n l lin ink ki kin ng g s spe pe ec ci ifi fic c c li li ipi pid d d ty ty type pe p s s s wi wi with h th earliest biological chemical entities studied by scientist, the concept of the "lipidome", which refers to the complete collection of chemically distinct lipids in a biological sample, is a relatively new term in the scientific literature, appearing after the turn of the century 12 . Since then, the field of lipidomics has grown at a rapid pace (Figure 1) , and now provides a powerful hypothesis-generating platform that is readily available to the scientific community. Lipidomics typically refers to mass spectrometric identification of individual lipid species, which can annotate the type, elemental composition (molecular weight), and component (e.g. fatty acid molecular species) composition, of a particular lipid species. Lipidome diversity arises through differences in the type and composition of distinct groups of lipids (e.g. sterols, phospholipids, triglycerides). Phospholipid composition diversity is governed by the makeup of the polar headgroup, which determines the class of the lipid (i.e. choline, ethanolamine, serine, etc.), the covalent nature of the linkage with fatty acid chains [i.e. acyl, alkyl (ether lipid), alkenyl (plasmalogen), amide (sphingolipids)], and the individual molecular species of fatty acids, which is influenced by the length of individual aliphatic chains of fatty acids, the amount and position of double bonds, and the regiospecificity of the aliphatic moieties (i.e. sn-1, sn-2, sn-3 position on the glycerol backbone). Mass spectrometry can differentiate amongst these aspects of complex lipids, though species which are isobaric (possess the same molecular weight) often are more difficult to distinguish without more precise approaches that involve both fragmentation in the mass spectrometer and/or chromatographic resolution on the front end leading into the instrument, typically through use of high performance lipid chromatography (HPLC). The work by Stegemann and colleagues 11 employed a targeted analysis that focused on a broad range of known lipids using what they termed a "shotgun lipidomics" approach, and relied on a direct lipid extract analysis without chromatographic separation. The shotgun lipidomics methodology riglycerides). Phospholipid composition diversity is governed by the makeup of f th the e e po po pola la lar r r headgroup, which determines the class of the lipid (i.e. choline, ethanolamine, serine, etc.), the co ova va vale le lent nt nt n n nat at atu ur ure of of of t the h linkage with fatty acid ch hai ai ains s [i.e. acyl, alk kyl y y (e eth th the er er lipid), alkenyl used has as its major advantages its simplicity, high sensitivity, ease of sample preparation, and instrument cost (can be done with both low and high end mass spectrometers).
However, the methodology employed also has several major disadvantages including: (i) the type of mass spectrometry used could not identify individual aliphatic species, but rather determined total carbon number for fatty acids in a compound; (ii) isobaric lipid species are not identified but rather cumulatively analyzed; and (iii) as performed, the methodology was only semi-quantitative, since synthetic isotope labeled internal standards for individual molecular species were not used. Furthermore, it is important to note that any data generated using lipidomic approaches rely heavily on the way the samples are stored [e.g. "freezer burn" is lipid peroxidation, and oxidative modifications and degradation of certain lipids may be particularly problematic unless special precautions are taken to prevent adventitious oxidation during storage Unfortunately, the study by Stegemann and colleagues 11 does not go further to determine the precise molecular species of lipids that comprise TAG-54:2, CE-16:1, and PC-36:5 and drive the associations identified with incident CVD risks. This information would have been ideally also leveraged for development of more specific quantitative mass spectrometry-based analyses of the precise molecular species involved, which would have ideally then been performed on both primary and validation cohorts. Knowledge of the precise molecular species may also have helped to reveal the underlying mechanism through which the identified SFA-and MUFA-rich lipids are linked to CVD risk. In fact, although this study provides one of the first looks into the CVD risk plasma lipidome, many further studies are required to both define the precise lipid molecular species that drive the associations discovered, and to understand underlying mechanisms behind the associations observed.
Although not expanded on in the work by Stegemann and colleagues 11 , there is ample evidence supporting a mechanistic link between SFA and MUFA metabolism in the pathogenesis of CVD. In fact, it has long been know that diets enriched in SFA promote CVD, in part by promoting hypercholesterolemia 14 . In addition to effects on hypercholesterolemia, SFAs have also been shown to activate pattern recognition receptors (PRR) such as the toll-like receptor 4 (TLR4), thereby promoting vascular inflammation and CVD (Figure 2 ) 15 . Likewise, MUFA rich diets promote atherosclerosis in animal models, yet epidemiological studies link MUFA-rich diets like the Mediterranean diet to beneficial effects on CVD 16 . While the reasons for this discrepancy between epidemiology and controlled animal studies are unknown, it has been suggested that it can likely be attributed to other dietary constituents in the Mediterranean diet that overrides the potential proatherogenic MUFA component 16 . Proatherogenic SFA and MUFA CVD risk plasma lipidome, many further studies are required to both define the pr p prec ec cis se e e li li lipi pi pid d d molecular species that drive the associations discovered, and to understand underlying me mech ch chan an ani is isms ms m b b beh hin in ind d the associations observed.
Althou ugh gh gh n n not t e e exp p pan an ande de ded d d on on n i in n n t th he e e wo ork k k by S St teg gem em man an nn n an and d co coll ll le e eag gu gues es es 11 11 11 , , th th her er e e e e is is is a a am mp mple l l points towards well studied enzymatic pathways.
For instance, the link between CE-16:1 and CVD found by Stegemann and colleagues 11 might in retrospect not be surprising given that the enzymatic source of MUFA enriched CE (acyl-coenzymeA:cholesterol acyltransferase 2, ACAT2) has long been linked to atherosclerosis development, and continues to be a potential drug target for CVD prevention 17, 18 . There are only two known enzymatic sources of circulating CE in mammals: 1) the intracellular enzyme ACAT2, which is expressed exclusively in enterocytes and hepatocytes where apoB-containing lipoproteins are made, and 2) the plasma enzyme lecithin:cholesterol acyltransferase (LCAT), which are tightly associated with lipoprotein carriers. There is also a much smal lle le er po po p ol ol ol o o of f f circulating free SFA and MUFA complexed to albumin, which is thought to be mostly co ont nt ntri ri ribu bu bute te ted d d by by b a adi di dip po pose tissue lipolysis. The work rk k b by y Stegemann an an and co co oll ll lle eagues 11 provides a snap h h hot ot t of this pla asm sm ma a a li li ipi pi p do do ome me m , , wh w whic ic ch h h is is p pr rima a ari i ily li ip po opr r rot ot tei ein n n-a as asso so oci iat ated ed ed c co omp mp mpl le lex x li li lipi pi pids ds ds (CE CE CE, , TG TG G,
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. A A A k k key ey c c con on nsi sid d der ra rati tion n n f f for or or t t the he he p p pla la asm sm sma a a li li ipi pi p d d dom me me is s s th th tha at l l lip ip i i id id m m mod od dif f fy yi ying ng g e e enz nz n ym ym ymes s di ic icta tat t te which catalyzes a two-step reaction that hydrolyzes the sn-2 fatty acyl chain of PC followed by transacylation of the release fatty acid to the 3 -hydroxyl group of cholesterol generating CE and LPC 17 . It is clear that these two enzymes have striking substrate preference, with ACAT2 preferring to esterify MUFA (generating CE-16:1 and CE-18:1, which are preferentially carried in apoB-containing lipoproteins) and LCAT preferring to esterify PUFA (generating CE-18:2, CE-20:4 and many other PUFA-CE, which are preferentially carried in HDL particles) 17, 18 .
Before the advent of unbiased lipidomics, several previous studies have shown that patient with coronary artery disease have higher MUFA-containing CE (ACAT2-derived) and lower levels of PUFA-containing CE (LCAT-derived), when compared to healthy controls 17 . This wellappreciated connection between MUFA-containing CE species and atherosclerosis development in mouse and man, may be explained in part by the fact the LDL particles enriched in ACAT2-derived CE (16:1 and 18:1) have enhanced ability to bind to arterial proteoglycans and may be preferentially retained in the artery wall more so than PUFA-enriched LDL 18 . Since there are no known circulating cholesteryl esterases to impact the plasma lipidome, therapeutic targeting of ACAT2 remains an attractive approach for limiting circulating CE-16:1 and CE-18:1 (the major CE species found in atheroma) 17 .
In addition to CE species, circulating TG levels have also long been associated with CVD risk. Therefore, association of a number of TG species (including TG-54:2) with CVD risk by (1 1 16:1 1 1 a a and n 18:1) have enhanced abili ity ty ty t to o bind to arteri ri ial a p pro ro ot te teoglycans and may be pref f fer e entially r ret et tai i ine ed d d in n n t t the he he a a ar rt rter er ry y y w w wa a all l mor re re so t th tha an P P PU UF UFA-A-A-en enr ri ric ch hed ed d L LD DL DL 18 18 18 . . Si Sinc nc nce e e th th ther ere e e ar ar re e n no kn know ow own n n ci circ rc cul ul ulat atin in ng ch cho o ole es este tery y yl l es es ste te tera ra rase ses s s to to to i i imp mp mpac ac a t t th h he e p pl plas as asm m ma l l lip ip i i id idom om ome, e, e, th he hera ra ape pe peut utic ic ic t t tar rg ge get ti ting ng g o of f ACAT2 rema ma ain in ins s s an an an a att tt ttra ra ract t tiv iv ive e e ap ap ppr pr p oa oa oach h h f for or or l l lim im mit it i i i ing ng ng c c cir i cu cu cula la ati ti ting ng ng C C CE--16 16 16:1 :1 1 a a and nd nd C C CE-E-E 18 18 18:1 :1 1 (the major r highly regulated but dynamic, and changes with the fasting vs. fed state of the individual. Thus, time of sampling relative to the last meal is critical and can significantly impact TG molecular species composition. One study has suggested that DGAT1 knockout mice are protected against atherosclerosis development, primarily due to decreased intestinal cholesterol absorption rates 19 .
However, whether circulating TGs are actually involved in CVD disease pathogenesis is an intense matter of debate. Some believe that since circulating TG are carried in the same lipoprotein class (apoB-containing) as proatherogenic CE, the TG are simply associated with disease and not causatively linked to disease pathogenesis. Support of this concept comes from ACAT2 knockout mice, which have no CE packaged into newly secreted VLDL particles, but instead fill the VLDL core with TG. These TG-rich VLDL completely lack the ability to promote atherosclerosis in mice 20 , supporting the notion that CE is the culprit lipid driving CVD in mice.
Hence it is possible that the TG forms associated with CVD in the study by Stegemann and colleagues 11 are simply associated lipids and not mechanistically linked to disease progression.
The work by Stegemann and colleagues 11 identifies an important link in both SFA-and MUFA-containing lipid species and CVD risk. It is therefore important to consider the enzyme that desaturates SFA to generate MUFA, known as stearoyl-CoA desaturase-1 (SCD1) 15 , and how it relates to the pathogenesis of atherosclerosis. Because of its role in generating the preferred substrate of TG biosynthesis, oleic acid (18:1), SCD1 has been a highly studied target for metabolic diseases such as obesity and diabetes 15 . In fact many major pharmaceutical companies have at one point had SCD1 inhibitor programs due to the fact that inhibition or genetic deletion of SCD1 in mice decreases TG biosynthesis and protects against diet-induced obesity and diabetes 15 . However, the role of SCD1 in CVD complicates such efforts. It turns out that either inhibition or genetic deletion of SCD1 causes a markedly advanced atherosclerotic nstead fill the VLDL core with TG. These TG-rich VLDL completely lack the ab ab bil ilit it i y y y to to to p p pro ro rom mote atherosclerosis in mice 20 , supporting the notion that CE is the culprit lipid driving CVD in mice.
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Th The e e wo w work rk k b b by y S S Steg eg gem eman an a n n n an an and d d co co oll l lea ea eag g gues es es 11 11 id de den nt ntif if fie ie ies s s an an n i imp mp mpor or orta ta ant nt nt l lin in nk k k in in in b b bot ot oth h h S S SFA A-A-a a and d d phenotype in mice 15 . It is thought that inhibition of SCD1 causes an atypical accumulation of SFA-enriched lipid in the circulation and in the artery wall, where SFA enrichment can enhance TLR4 signaling and vascular inflammation 15 . These studies highlight the fact that altering the ratio of SFA and MUFA can dramatically alter macrophage inflammatory responses and associated vascular inflammation, implicating SFA-enriched lipids in the pathogenesis of CVD.
Ultimately, mechanistic animal studies for lipid metabolic enzymes (ACAT2, DGAT1, SCD1, etc.) are necessary to provide clues into whether certain lipid classes are simply associated with disease or mechanistically linked to disease pathogenesis.
In conclusion, the study by Stegemann and colleagues provides an early glimpse into the plasma lipidome of CVD. It is important to mention that one prominent strength of this study is the application of unbiased lipidomic technology to a prospective cohort with incident CVD endpoint data. However, there are several limitations that leave unanswered questions: 1) The shotgun lipidomics methods employed do not provide identification amongst isobaric species, so the specific molecular species that are a part of the CVD risk signature remain unknown.
Related, whether more accurate quantification of the molecular species that constitute the "signature lipids" identified can be validated in independent prospective cohorts employing more specific mass spectrometry based analyses remains unknown; and 2) How does the plasma lipidome change temporally during key phases of atherosclerosis progression and/or regression? and 3) Can the associations observed be leveraged, such as through genetic analyses, to mechanistically explore the pathways potentially involved for evidence of causal relationships with CVD in humans. In addition to these unanswered questions, it remains extremely important for the field of lipidomics in general to progress from simple descriptive lists of lipids that associate with human disease to mechanistic studies linking identified lipids to the pathogenesis plasma lipidome of CVD. It is important to mention that one prominent strength h o of f th this is is s s stu tu tudy dy dy i is he application of unbiased lipidomic technology to a prospective cohort with incident CVD r r en ndp dp dpoi oi oint nt nt d d dat at ata a a. H How ow owe ever, there are several limita a ati ti tion on ns that leave u una n n ns swe we wer red questions: 1) The h h hot ot tgu g n lipido omi m mics s m me etho ho hod ds ds e em mp mplo lo loy ye yed d d d d do not ot pro ovi ide i id de dent nt tif f fic ica at tio o on n am am mo on ongs gs gst t is isob ob bar ar ric ic ic s s spe pe eci cie e es, , so h he e e sp sp spec ec e if ific ic c m m mol ole e ecu ul ular ar r s sp pe peci c es es es t t tha ha hat t t a ar are e a a pa pa part rt rt o o of f f th th he e CV CV VD D D ri ri risk sk sk s s sig ig gna na atu tu ture re e r re em emai ai a n n n un un nkn kn know w wn. n. .
Related, whe eth th ther er e m m mor or o e e e ac a a cu cu cura ra rate e eua ua uant n n if if fic ic icat at a io io ion n n of of of t the he he m mol ol olec ec ecul ul u ar ar ar s s spe pe eci ci c es es es t tha ha hat t t co co ons ns nsti ti titu tu tute te t the of disease. In other words, lipidomics can provide useful data for identification of disease biomarkers or candidate species as was done in the work by Stegemann and colleagues 11 .
However, such data should also be used as a hypothesis-generating tool to examine enzymatic pathways that regulate such lipids in an attempt to therapeutically intervene. Moving beyond provision of descriptive lipidomic lists to mechanistic studies using defined animal model systems is recommended. Indeed, it is an exciting time for the field of lipidomics, where we are no longer limited by technology, and innovative ideas will be the only limitation moving forward. Undoubtedly, lipidomics provides a rich resource of new information linking metabolism to human disease [3] [4] [5] [6] [7] [8] [9] [10] [11] , and will be an important tool for drug discovery moving forward. ) ca a an n n pr p p ef ef efer er e en en enti ial al ally ly y b b be e e re re reta ta ain in ned ed e o o on n n ar ar arte te teri ri rial al al p pro ro rote te teog og ogly ly lyca ca c ns ns ns, , , an an and d d th t ereby
